BOSTON--(BUSINESS WIRE)--Signet Therapeutics, a biotech company using organoid disease models and AI to advance targeted cancer therapy, today announced that the FDA has granted its IND application ...

Signet Therapeutics founder Haisheng Zhang is betting on organoids and AI to outsmart diffuse gastric cancer and the limits of traditional “clean” drug design.

Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant syndrome predominantly driven by germline mutations in the CDH1 gene, which encodes the cell–cell adhesion molecule E-cadherin.

Gastric signet ring cell carcinoma (GSRCC) is a distinct subtype of gastric cancer (GC) with unique epidemiological and pathogenic characteristics. Despite its clinical significance, large-scale ...

Few areas of the body face more daily stress and potential damage than the stomach, which must manage everything we swallow.

(A) Unsupervised clustering of 112 GSRCC cases identified key proteins with significant differences between tumors and NATs, focusing on the top 100 proteins with a FC > 1.5 and P value < 0.05. (B) ...

A Hillsboro father of four has been diagnosed with a rare form of cancer and is preparing for a complex surgery at a Texas ...

Gastric (stomach) cancer remains one of the most common and deadly cancers in East Asia, including Korea. Yet despite its high prevalence, it has received far less molecular attention than colorectal ...